Diabetes mellitus is characterized by long standing hyperglycemia leading to numerous life-threatening complications. For type 1 diabetes mellitus, resulting from selective destruction of insulin producing cells by exaggerated immune reaction, the only effective therapy remains exogenous insulin administration. Despite accurate compliance to treatment of certain patients, transient episodes of hyperglycemia cannot be completely eliminated by this symptomatic treatment. Novel immunotherapeutic approaches based on tolerogenic dendritic cells, T regulatory cells and mesenchymal stem cells (MSCs) have been tested in clinical trials, endeavoring to directly modulate the autoimmune destruction process in pancreas. However, hyperglycemia itself affects the immune system and the final efficacy of cell-based immunotherapies could be affected by the different glycemic control of enrolled patients. The present review explores the impact of hyperglycemia on immune cells while providing greater insight into the molecular mechanisms of high glucose action and subsequent metabolic reprogramming of different immune cells. Furthermore, over-production of mitochondrial reactive oxygen species, formation of advanced glycation end products as a consequence of hyperglycemia and their downstream signalization in immune cells are also discussed. Since hyperglycemia in patients with type 1 diabetes mellitus might have an impact on immune-interventional treatment, the maintenance of a tight glucose control seems to be beneficial in patients considered for cell-based therapy.

Department of Immunology 2nd Faculty of Medicine University Hospital Motol Charles University Prague Prague Czechia

Department of Pediatrics Charles University Prague 2nd Faculty of Medicine University Hospital Motol Prague Czechia

SOTIO a s Prague Czechia

Zobrazit více v PubMed

Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, et al. . Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes (2017) 66:241–55. 10.2337/db16-0806 PubMed DOI PMC

Amersfoort J, Kuiper J. T cell metabolism in metabolic disease-associated autoimmunity. Immunobiology (2017) 222:925–36. 10.1016/j.imbio.2017.03.001 PubMed DOI

Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. (2005) 353:2643–53. 10.1056/NEJMoa052187 PubMed DOI PMC

Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care (2003) 26:510–3. 10.2337/diacare.26.2.510 PubMed DOI

Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. (1999) 26:259–65. PubMed

Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci. (2016) 351:201–11. 10.1016/j.amjms.2015.11.011 PubMed DOI

Yip L, Fuhlbrigge R, Taylor C, Creusot RJ, Nishikawa-Matsumura T, Whiting CC, et al. . Inflammation and hyperglycemia mediate Deaf1 splicing in the pancreatic lymph nodes via distinct pathways during type 1 diabetes. Diabetes (2015) 64:604–17. 10.2337/db14-0803 PubMed DOI PMC

Menart-Houtermans B, Rutter R, Nowotny B, Rosenbauer J, Koliaki C, Kahl S, et al. . Leukocyte profiles differ between type 1 and type 2 diabetes and are associated with metabolic phenotypes: results from the German Diabetes Study (GDS). Diabetes Care (2014) 37:2326–33. 10.2337/dc14-0316 PubMed DOI

Yao K, Ge JB, Sun AJ, Hong XW, Shi HY, Huang RC, et al. . Effects and mechanism of hyperglycemia on development and maturation and immune function of human monocyte derived dendritic cells. Zhonghua Xin Xue Guan Bing Za Zhi (2006) 34:60–4. PubMed

Han XQ, Gong ZJ, Xu SQ, Li X, Wang LK, Wu SM, et al. . Advanced glycation end products promote differentiation of CD4(+) T helper cells toward pro-inflammatory response. J Huazhong Univ Sci Technolog Med Sci. (2014) 34:10–7. 10.1007/s11596-014-1224-1 PubMed DOI

Kumar P, Natarajan K, Shanmugam N. High glucose driven expression of pro-inflammatory cytokine and chemokine genes in lymphocytes: molecular mechanisms of IL-17 family gene expression. Cell Signal (2014) 26:528–39. 10.1016/j.cellsig.2013.11.031 PubMed DOI

Dáňová K, Grohova A, Strnadova P, Funda DP, Sumnik Z, Lebl J, et al. . Tolerogenic dendritic cells from poorly compensated type 1 diabetes patients have decreased ability to induce stable antigen-specific T cell hyporesponsiveness and generation of suppressive regulatory T cells. J Immunol. (2017) 198:729–40. 10.4049/jimmunol.1600676 PubMed DOI

Roep BO, Tree TI. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol. (2014) 10:229–42. 10.1038/nrendo.2014.2 PubMed DOI

Arif S, Moore F, Marks K, Bouckenooghe T, Dayan CM, Planas R, et al. . Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes (2011) 60:2112–9. 10.2337/db10-1643 PubMed DOI PMC

Segovia-Gamboa N, Rodriguez-Arellano ME, Rangel-Cruz R, Sanchez-Diaz M, Ramirez-Reyes JC, Faradji R, et al. . Tolerogenic dendritic cells induce antigen-specific hyporesponsiveness in insulin- and glutamic acid decarboxylase 65-autoreactive T lymphocytes from type 1 diabetic patients. Clin Immunol. (2014) 154:72–83. 10.1016/j.clim.2014.06.009 PubMed DOI

Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care (2011) 34:2026–32. 10.2337/dc11-0472 PubMed DOI PMC

Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Derkowska I, Juscinska J, et al. . Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin Immunol. (2014) 153:23–30. 10.1016/j.clim.2014.03.016 PubMed DOI

Creusot RJ, Giannoukakis N, Trucco M, Clare-Salzler MJ, Fathman CG. It's time to bring dendritic cell therapy to type 1 diabetes. Diabetes (2014) 63:20–30. 10.2337/db13-0886 PubMed DOI PMC

Farooq T, Rehman K, Hameed A, Akash MSH. Stem cell therapy and type 1 diabetes mellitus: treatment strategies and future perspectives. Adv Exp Med Biol. (2018). 10.1007/5584_2018_195. [Epub ahead of print]. PubMed DOI

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, et al. . Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. (2015) 7:315ra189. 10.1126/scitranslmed.aad4134 PubMed DOI PMC

Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J, et al. . Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care (2012) 35:1817–20. 10.2337/dc12-0038 PubMed DOI PMC

Marek-Trzonkowska N, Mysliwiec M, Iwaszkiewicz-Grzes D, Gliwinski M, Derkowska I, Zalinska M, et al. . Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes. J Transl Med. (2016) 14:332. 10.1186/s12967-016-1090-7 PubMed DOI PMC

Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes (2015) 64:587–92. 10.2337/db14-0656 PubMed DOI

Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, et al. . Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care (2016) 39:149–57. 10.2337/dc15-0171 PubMed DOI

Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, et al. . Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care (2011) 34:2567–9. 10.2337/dc11-1406 PubMed DOI PMC

Haller MJ, Wasserfall CH, McGrail KM, Cintron M, Brusko TM, Wingard JR, et al. . Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care (2009) 32:2041–6. 10.2337/dc09-0967 PubMed DOI PMC

Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, et al. . Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med. (2012) 10:3. 10.1186/1741-7015-10-3 PubMed DOI PMC

Delgado E, Perez-Basterrechea M, Suarez-Alvarez B, Zhou H, Revuelta EM, Garcia-Gala JM, et al. . Modulation of autoimmune T-cell memory by stem cell educator therapy: phase 1/2 clinical trial. EBioMedicine (2015) 2:2024–36. 10.1016/j.ebiom.2015.11.003 PubMed DOI PMC

Dave SD, Vanikar AV, Trivedi HL, Thakkar UG, Gopal SC, Chandra T. Novel therapy for insulin-dependent diabetes mellitus: infusion of in vitro-generated insulin-secreting cells. Clin Exp Med. (2015) 15:41–5. 10.1007/s10238-013-0266-1 PubMed DOI

Ceriello A. Hypothesis: the “metabolic memory”, the new challenge of diabetes. Diabetes Res Clin Pract. (2009) 86(Suppl. 1):S2–6. 10.1016/S0168-8227(09)70002-6 PubMed DOI

Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes (2005) 54:1615–25. 10.2337/diabetes.54.6.1615 PubMed DOI

Yan LJ. Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. J Diabetes Res. (2014) 2014:137919. 10.1155/2014/137919 PubMed DOI PMC

Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia (2001) 44:129–46. 10.1007/s001250051591 PubMed DOI

Gholap NN, Davies MJ, Mostafa SA, Khunti K. Diagnosing type 2 diabetes and identifying high-risk individuals using the new glycated haemoglobin (HbA1c) criteria. Br J Gen Pract. (2013) 63:e165–7. 10.3399/bjgp13X663244 PubMed DOI PMC

Vistoli G, De Maddis D, Cipak A, Zarkovic N, Carini M, Aldini G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res. (2013) 47(Suppl. 1):3–27. 10.3109/10715762.2013.815348 PubMed DOI

Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci. (2011) 1243:88–102. 10.1111/j.1749-6632.2011.06320.x PubMed DOI PMC

Ihnat MA, Thorpe JE, Kamat CD, Szabo C, Green DE, Warnke LA, et al. . Reactive oxygen species mediate a cellular ‘memory' of high glucose stress signalling. Diabetologia (2007) 50:1523–31. 10.1007/s00125-007-0684-2 PubMed DOI

Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. . Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. (1992) 267:14998–5004. PubMed

Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. (1999) 274:19919–24. PubMed

Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. (2014) 2:411–29. 10.1016/j.redox.2013.12.016 PubMed DOI PMC

Wang M, Zhang W, Xu S, Peng L, Wang Z, Liu H, et al. . TRB3 mediates advanced glycation end product-induced apoptosis of pancreatic beta-cells through the protein kinase C beta pathway. Int J Mol Med. (2017) 40:130–36. 10.3892/ijmm.2017.2991 PubMed DOI PMC

Brisslert M, Amu S, Pullerits R. Intra-peritoneal sRAGE treatment induces alterations in cellular distribution of CD19(+), CD3 (+) and Mac-1 (+) cells in lymphoid organs and peritoneal cavity. Cell Tissue Res. (2013) 351:139–48. 10.1007/s00441-012-1508-3 PubMed DOI

Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. . The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. (2003) 198:1507–15. 10.1084/jem.20030800 PubMed DOI PMC

Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, et al. . RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. (2008) 181:4272–8. 10.4049/jimmunol.181.6.4272 PubMed DOI PMC

Giannoukakis N. Tolerogenic dendritic cells for Type 1 diabetes. Immunotherapy (2013) 5:569–71. 10.2217/imt.13.50 PubMed DOI

Roep B. Immune Intervention With Tolerogenic Dendritic Cells in Type 1 Diabetes. A Phase 1 Safety Study Called D-sense. Clinical Trial no NTR5542 (2015) Available online at: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5542

Everts B, Amiel E, van der Windt GJ, Freitas TC, Chott R, Yarasheski KE, et al. . Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood (2012) 120:1422–31. 10.1182/blood-2012-03-419747 PubMed DOI PMC

Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, et al. . Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood (2010) 115:4742–9. 10.1182/blood-2009-10-249540 PubMed DOI PMC

Sim WJ, Ahl PJ, Connolly JE. Metabolism is central to tolerogenic dendritic cell function. Mediators Inflamm. (2016) 2016:2636701. 10.1155/2016/2636701 PubMed DOI PMC

Nikolic T, Woittiez NJC, van der Slik A, Laban S, Joosten A, Gysemans C, et al. . Differential transcriptome of tolerogenic versus inflammatory dendritic cells points to modulated T1D genetic risk and enriched immune regulation. Genes Immun. (2017) 18:176–83. 10.1038/gene.2017.18 PubMed DOI

Adorini L, Penna G. Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handb Exp Pharmacol. (2009) 188:251–73. PubMed

van Kooten C, Stax AS, Woltman AM, Gelderman KA. Handjournal of experimental pharmacology “dendritic cells”: the use of dexamethasone in the induction of tolerogenic DCs. Handb Exp Pharmacol. (2009) 233–49. 10.1007/978-3-540-71029-5_11 PubMed DOI

Malinarich F, Duan K, Hamid RA, Bijin A, Lin WX, Poidinger M, et al. . High mitochondrial respiration and glycolytic capacity represent a metabolic phenotype of human tolerogenic dendritic cells. J Immunol. (2015) 194:5174–86. 10.4049/jimmunol.1303316 PubMed DOI

Ferreira GB, Vanherwegen AS, Eelen G, Gutierrez AC, Van Lommel L, Marchal K, et al. Vitamin D3 induces tolerance in human dendritic cells by activation of intracellular metabolic pathways. Cell Rep. (2015) 10:711–25. 10.1016/j.celrep.2015.01.013 PubMed DOI

Dáňová K, Klapetkova A, Kayserova J, Sediva A, Spisek R, Jelinkova LP. NF-kappaB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. Oncotarget (2015) 6:14123–38. 10.18632/oncotarget.4234 PubMed DOI PMC

Procaccini C, Galgani M, De Rosa V, Matarese G. Intracellular metabolic pathways control immune tolerance. Trends Immunol. (2012) 33:1–7. 10.1016/j.it.2011.09.002 PubMed DOI

Patel SR, Xu Y, Koenig RJ, Hsu CH. Effect of glucose on the function of the calcitriol receptor and vitamin D metabolism. Kidney Int. (1997) 52:79–86. PubMed

Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol. (2009) 39:3147–59. 10.1002/eji.200839103 PubMed DOI

Waschbisch A, Sanderson N, Krumbholz M, Vlad G, Theil D, Schwab S, et al. . Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients. PLoS ONE (2014) 9:e115488. 10.1371/journal.pone.0115488 PubMed DOI PMC

Hernandez-Sanchez F, Guzman-Beltran S, Herrera MT, Gonzalez Y, Salgado M, Fabian G, et al. . High glucose induces O-GlcNAc glycosylation of the vitamin D receptor (VDR) in THP1 cells and in human macrophages derived from monocytes. Cell Biol Int. (2017) 41:1065–74. 10.1002/cbin.10827 PubMed DOI

Somjen D, Knoll E, Sharon O, Many A, Stern N. Calciotrophic hormones and hyperglycemia modulate vitamin D receptor and 25 hydroxyy vitamin D 1-alpha hydroxylase mRNA expression in human vascular smooth muscle cells. J Steroid Biochem Mol Biol. (2015) 148:210–3. 10.1016/j.jsbmb.2014.11.007 PubMed DOI

Gilardini Montani MS, Granato M, Cuomo L, Valia S, Di Renzo L, D'Orazi G, et al. . High glucose and hyperglycemic sera from type 2 diabetic patients impair DC differentiation by inducing ROS and activating Wnt/beta-catenin and p38 MAPK. Biochim Biophys Acta (2016) 1862:805–13. 10.1016/j.bbadis.2016.01.001 PubMed DOI

Mollah ZU, Pai S, Moore C, O'Sullivan BJ, Harrison MJ, Peng J, et al. . Abnormal NF-kappa B function characterizes human type 1 diabetes dendritic cells and monocytes. J Immunol. (2008) 180:3166–75. 10.4049/jimmunol.180.5.3166 PubMed DOI

Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. . Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes (2001) 50:2792–808. 10.2337/diabetes.50.12.2792 PubMed DOI

Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis. (2010) 69:2042–50. 10.1136/ard.2009.126383 PubMed DOI PMC

Boks MA, Kager-Groenland JR, Haasjes MS, Zwaginga JJ, van Ham SM, ten Brinke A. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction–a comparative study of human clinical-applicable DC. Clin Immunol. (2012) 142:332–42. 10.1016/j.clim.2011.11.011 PubMed DOI

Lu H, Yao K, Huang D, Sun A, Zou Y, Qian J, et al. . High glucose induces upregulation of scavenger receptors and promotes maturation of dendritic cells. Cardiovasc Diabetol. (2013) 12:80. 10.1186/1475-2840-12-80 PubMed DOI PMC

Buttari B, Profumo E, Capozzi A, Facchiano F, Saso L, Sorice M, et al. Advanced glycation end products of human beta(2) glycoprotein I modulate the maturation and function of DCs. Blood (2011) 117:6152–61. 10.1182/blood-2010-12-325514 PubMed DOI

Ge J, Jia Q, Liang C, Luo Y, Huang D, Sun A, et al. . Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol. (2005) 25:2157–63. 10.1161/01.ATV.0000181744.58265.63 PubMed DOI

Buttari B, Profumo E, Facchiano F, Ozturk EI, Segoni L, Saso L, et al. . Resveratrol prevents dendritic cell maturation in response to advanced glycation end products. Oxid Med Cell Longev. (2013) 2013:574029. 10.1155/2013/574029 PubMed DOI PMC

Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, et al. . Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol. (2010) 185:1037–44. 10.4049/jimmunol.0903586 PubMed DOI PMC

Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, et al. . Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity (2013) 38:225–36. 10.1016/j.immuni.2012.10.020 PubMed DOI PMC

MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol. (2013) 31:259–83. 10.1146/annurev-immunol-032712-095956 PubMed DOI PMC

Chang CH, Curtis JD, Maggi LB, Jr, Faubert B, Villarino AV, O'Sullivan D, et al. . Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell (2013) 153:1239–51. 10.1016/j.cell.2013.05.016 PubMed DOI PMC

Martinez N, Vallerskog T, West K, Nunes-Alves C, Lee J, Martens GW, et al. . Chromatin decondensation and T cell hyperresponsiveness in diabetes-associated hyperglycemia. J Immunol. (2014) 193:4457–68. 10.4049/jimmunol.1401125 PubMed DOI PMC

Monti P, Brigatti C, Krasmann M, Ziegler AG, Bonifacio E. Concentration and activity of the soluble form of the interleukin-7 receptor alpha in type 1 diabetes identifies an interplay between hyperglycemia and immune function. Diabetes (2013) 62:2500–8. 10.2337/db12-1726 PubMed DOI PMC

Torres-Aguilar H, Sanchez-Torres C, Jara LJ, Blank M, Shoenfeld Y. IL-10/TGF-beta-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals. J Clin Immunol. (2010) 30:659–68. 10.1007/s10875-010-9430-5 PubMed DOI

Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci. (2008) 1126:7–13. 10.1196/annals.1433.056 PubMed DOI PMC

Jaisson S, Souchon PF, Desmons A, Salmon AS, Delemer B, Gillery P. Early formation of serum advanced glycation end-products in children with type 1 diabetes mellitus: relationship with glycemic control. J Pediatr. (2016) 172:56–62. 10.1016/j.jpeds.2016.01.066 PubMed DOI

Akirav EM, Preston-Hurlburt P, Garyu J, Henegariu O, Clynes R, Schmidt AM, et al. . RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS ONE (2012) 7:e34698. 10.1371/journal.pone.0034698 PubMed DOI PMC

Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC, Type 1 Diabetes TrialNet Study Group. The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus. J Immunol. (2016) 197:3076–85. 10.4049/jimmunol.1600197 PubMed DOI PMC

Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, et al. . Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. (2009) 182:259–73. 10.4049/jimmunol.182.1.259 PubMed DOI PMC

Jeker LT, Bour-Jordan H, Bluestone JA. Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med. (2012) 2:a007807. 10.1101/cshperspect.a007807 PubMed DOI PMC

Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes (2005) 54:92–9. 10.2337/diabetes.54.1.92 PubMed DOI

Zhang Y, Bandala-Sanchez E, Harrison LC. Revisiting regulatory T cells in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. (2012) 19:271–8. 10.1097/MED.0b013e328355a2d5 PubMed DOI

Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, Schatz D, et al. . No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes (2007) 56:604–12. 10.2337/db06-1248 PubMed DOI

Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes (2005) 54:1407–14. 10.2337/diabetes.54.5.1407 PubMed DOI

Haseda F, Imagawa A, Murase-Mishiba Y, Terasaki J, Hanafusa T. CD4(+) CD45RA(-) FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin Exp Immunol. (2013) 173:207–16. 10.1111/cei.12116 PubMed DOI PMC

Singh K, Kadesjo E, Lindroos J, Hjort M, Lundberg M, Espes D, et al. . Interleukin-35 administration counteracts established murine type 1 diabetes–possible involvement of regulatory T cells. Sci Rep. (2015) 5:12633. 10.1038/srep12633 PubMed DOI PMC

Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, et al. . Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes (2010) 59:407–15. 10.2337/db09-0694 PubMed DOI PMC

McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, et al. . Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. (2011) 186:3918–26. 10.4049/jimmunol.1003099 PubMed DOI PMC

Marwaha AK, Crome SQ, Panagiotopoulos C, Berg KB, Qin H, Ouyang Q, et al. . Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol. (2010) 185:3814–8. 10.4049/jimmunol.1001860 PubMed DOI

Hull CM, Nickolay LE, Estorninho M, Richardson MW, Riley JL, Peakman M, et al. . Generation of human islet-specific regulatory T cells by TCR gene transfer. J Autoimmun. (2017) 79:63–73. 10.1016/j.jaut.2017.01.001 PubMed DOI

Glisic-Milosavljevic S, Wang T, Koppen M, Kramer J, Ehlenbach S, Waukau J, et al. . Dynamic changes in CD4+ CD25+(high) T cell apoptosis after the diagnosis of type 1 diabetes. Clin Exp Immunol. (2007) 150:75–82. 10.1111/j.1365-2249.2007.03475.x PubMed DOI PMC

Jailwala P, Waukau J, Glisic S, Jana S, Ehlenbach S, Hessner M, et al. . Apoptosis of CD4+ CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS ONE (2009) 4:e6527. 10.1371/journal.pone.0006527 PubMed DOI PMC

Tan T, Xiang Y, Chang C, Zhou Z. Alteration of regulatory T cells in type 1 diabetes mellitus: a comprehensive review. Clin Rev Allergy Immunol. (2014) 47:234–43. 10.1007/s12016-014-8440-0 PubMed DOI

De Rosa V, Galgani M, Porcellini A, Colamatteo A, Santopaolo M, Zuchegna C, et al. . Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol. (2015) 16:1174–84. 10.1038/ni.3269 PubMed DOI PMC

Procaccini C, Carbone F, Di Silvestre D, Brambilla F, De Rosa V, Galgani M, et al. The proteomic landscape of human ex vivo regulatory and conventional T cells reveals specific metabolic requirements. Immunity (2016) 44:406–21. 10.1016/j.immuni.2016.01.028 PubMed DOI PMC

Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes (2005) 54:85–91. 10.2337/diabetes.54.1.85 PubMed DOI

Gao Z, Gao Y, Li Z, Chen Z, Lu D, Tsun A, et al. . Synergy between IL-6 and TGF-beta signaling promotes FOXP3 degradation. Int J Clin Exp Pathol. (2012) 5:626–33. PubMed PMC

Zhen Y, Sun L, Liu H, Duan K, Zeng C, Zhang L, et al. . Alterations of peripheral CD4+CD25+Foxp3+ T regulatory cells in mice with STZ-induced diabetes. Cell Mol Immunol. (2012) 9:75–85. 10.1038/cmi.2011.37 PubMed DOI PMC

Ryba M, Rybarczyk-Kapturska K, Zorena K, Mysliwiec M, Mysliwska J. Lower frequency of CD62L(high) and higher frequency of TNFR2(+) Tregs are associated with inflammatory conditions in type 1 diabetic patients. Mediators Inflamm. (2011) 2011:645643. 10.1155/2011/645643 PubMed DOI PMC

Stechova K, Sklenarova-Labikova J, Kratzerova T, Pithova P, Filipp D. Not only glycaemic but also other metabolic factors affect T regulatory cell counts and proinflammatory cytokine levels in women with type 1 diabetes. J Diabetes Res. (2017) 2017:5463273. 10.1155/2017/5463273 PubMed DOI PMC

El-Samahy MH, Adly AA, Ismail EA, Salah NY. Regulatory T cells with CD62L or TNFR2 expression in young type 1 diabetic patients: relation to inflammation, glycemic control and micro-vascular complications. J Diabetes Complications (2015) 29:120–6. 10.1016/j.jdiacomp.2014.07.004 PubMed DOI

Okubo Y, Torrey H, Butterworth J, Zheng H, Faustman DL. Treg activation defect in type 1 diabetes: correction with TNFR2 agonism. Clin Transl Immunol. (2016) 5:e56. 10.1038/cti.2015.43 PubMed DOI PMC

El-Badri N, Ghoneim MA. Mesenchymal stem cell therapy in diabetes mellitus: progress and challenges. J Nucleic Acids (2013) 2013:194858. 10.1155/2013/194858 PubMed DOI PMC

Katuchova J, Harvanova D, Spakova T, Kalanin R, Farkas D, Durny P, et al. . Mesenchymal stem cells in the treatment of type 1 diabetes mellitus. Endocr Pathol. (2015) 26:95–103. 10.1007/s12022-015-9362-y PubMed DOI

Hashemian SJ, Kouhnavard M, Nasli-Esfahani E. Mesenchymal stem cells: rising concerns over their application in treatment of type one diabetes mellitus. J Diabetes Res. (2015) 2015:675103. 10.1155/2015/675103 PubMed DOI PMC

Cho J, D'Antuono M, Glicksman M, Wang J, Jonklaas J. A review of clinical trials: mesenchymal stem cell transplant therapy in type 1 and type 2 diabetes mellitus. Am J Stem Cells (2018) 7:82–93. PubMed PMC

Zhang D, Lu H, Chen Z, Wang Y, Lin J, Xu S, et al. . High glucose induces the aging of mesenchymal stem cells via Akt/mTOR signaling. Mol Med Rep (2017) 16:1685–90. 10.3892/mmr.2017.6832 PubMed DOI PMC

Zhang X, Meng K, Pu Y, Wang C, Chen Y, Wang L. Hyperglycemia altered the fate of cardiac stem cells to adipogenesis through inhibiting the beta-catenin/TCF-4 pathway. Cell Physiol Biochem. (2018) 49:2254–63. 10.1159/000493828 PubMed DOI

Deng X, Xu M, Shen M, Cheng J. Effects of type 2 diabetic serum on proliferation and osteogenic differentiation of mesenchymal stem cells. J Diabetes Res. (2018) 2018:5765478. 10.1155/2018/5765478 PubMed DOI PMC

Denu RA, Hematti P. Effects of oxidative stress on mesenchymal stem cell biology. Oxid Med Cell Longev. (2016) 2016:2989076. 10.1155/2016/2989076 PubMed DOI PMC

Aikawa E, Fujita R, Asai M, Kaneda Y, Tamai K. Receptor for advanced glycation end products-mediated signaling impairs the maintenance of bone marrow mesenchymal stromal cells in diabetic model mice. Stem Cells Dev. (2016) 25:1721–32. 10.1089/scd.2016.0067 PubMed DOI

Zhu G, Chai J, Ma L, Duan H, Zhang H. Downregulated microRNA-32 expression induced by high glucose inhibits cell cycle progression via PTEN upregulation and Akt inactivation in bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun. (2013) 433:526–31. 10.1016/j.bbrc.2013.03.018 PubMed DOI

Saki N, Jalalifar MA, Soleimani M, Hajizamani S, Rahim F. Adverse effect of high glucose concentration on stem cell therapy. Int J Hematol Oncol Stem Cell Res (2013) 7:34–40. PubMed PMC

Kornicka K, Houston J, Marycz K. Dysfunction of mesenchymal stem cells isolated from metabolic syndrome and type 2 diabetic patients as result of oxidative stress and autophagy may limit their potential therapeutic use. Stem Cell Rev. (2018) 14:337–45. 10.1007/s12015-018-9809-x PubMed DOI PMC

Chen ACH, Lee YL, Fong SW, Wong CCY, Ng EHY, Yeung WSB. Hyperglycemia impedes definitive endoderm differentiation of human embryonic stem cells by modulating histone methylation patterns. Cell Tissue Res. (2017) 368:563–78. 10.1007/s00441-017-2583-2 PubMed DOI

Berezin A. Metabolic memory phenomenon in diabetes mellitus: achieving and perspectives. Diabetes Metab Syndr. (2016) 10:S176–83. 10.1016/j.dsx.2016.03.016 PubMed DOI

Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, et al. . Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. (2017) 76:227–34. 10.1136/annrheumdis-2015-208456 PubMed DOI PMC

Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, et al. . Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2009) 58:652–62. 10.2337/db08-1168 PubMed DOI PMC

Lei LT, Chen JB, Zhao YL, Yang SP, He L. Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. (2016) 20:1203–13. PubMed

Myeloid - derived suppressor cells in Type 1 diabetes are an expanded population exhibiting diverse T-cell suppressor mechanisms

Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications

Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?